176 related articles for article (PubMed ID: 26134286)
1. 2-Deoxy-d-Glucose Can Complement Doxorubicin and Sorafenib to Suppress the Growth of Papillary Thyroid Carcinoma Cells.
Wang SY; Wei YH; Shieh DB; Lin LL; Cheng SP; Wang PW; Chuang JH
PLoS One; 2015; 10(7):e0130959. PubMed ID: 26134286
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status.
Broecker-Preuss M; Müller S; Britten M; Worm K; Schmid KW; Mann K; Fuhrer D
BMC Cancer; 2015 Mar; 15():184. PubMed ID: 25879531
[TBL] [Abstract][Full Text] [Related]
3. Synergistic anti-proliferative effect of metformin and sorafenib on growth of anaplastic thyroid cancer cells and their stem cells.
Chen G; Nicula D; Renko K; Derwahl M
Oncol Rep; 2015 Apr; 33(4):1994-2000. PubMed ID: 25683253
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib and Quinacrine Target Anti-Apoptotic Protein MCL1: A Poor Prognostic Marker in Anaplastic Thyroid Cancer (ATC).
Abdulghani J; Gokare P; Gallant JN; Dicker D; Whitcomb T; Cooper T; Liao J; Derr J; Liu J; Goldenberg D; Finnberg NK; El-Deiry WS
Clin Cancer Res; 2016 Dec; 22(24):6192-6203. PubMed ID: 27307592
[TBL] [Abstract][Full Text] [Related]
5. A novel combination of withaferin A and sorafenib shows synergistic efficacy against both papillary and anaplastic thyroid cancers.
Cohen SM; Mukerji R; Timmermann BN; Samadi AK; Cohen MS
Am J Surg; 2012 Dec; 204(6):895-900; discussion 900-1. PubMed ID: 23231932
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib and 2-Deoxyglucose Synergistically Inhibit Proliferation of Both Sorafenib-Sensitive and -Resistant HCC Cells by Inhibiting ATP Production.
Reyes R; Wani NA; Ghoshal K; Jacob ST; Motiwala T
Gene Expr; 2017 Feb; 17(2):129-140. PubMed ID: 27938509
[TBL] [Abstract][Full Text] [Related]
7. Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK-mTORC1 signaling.
Fumarola C; Caffarra C; La Monica S; Galetti M; Alfieri RR; Cavazzoni A; Galvani E; Generali D; Petronini PG; Bonelli MA
Breast Cancer Res Treat; 2013 Aug; 141(1):67-78. PubMed ID: 23963659
[TBL] [Abstract][Full Text] [Related]
8. The multikinase inhibitor Sorafenib enhances glycolysis and synergizes with glycolysis blockade for cancer cell killing.
Tesori V; Piscaglia AC; Samengo D; Barba M; Bernardini C; Scatena R; Pontoglio A; Castellini L; Spelbrink JN; Maulucci G; Puglisi MA; Pani G; Gasbarrini A
Sci Rep; 2015 Mar; 5():9149. PubMed ID: 25779766
[TBL] [Abstract][Full Text] [Related]
9. Aberrant overexpression of pyruvate kinase M2 is associated with aggressive tumor features and the BRAF mutation in papillary thyroid cancer.
Feng C; Gao Y; Wang C; Yu X; Zhang W; Guan H; Shan Z; Teng W
J Clin Endocrinol Metab; 2013 Sep; 98(9):E1524-33. PubMed ID: 23846818
[TBL] [Abstract][Full Text] [Related]
10. Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E.
Lee MH; Lee SE; Kim DW; Ryu MJ; Kim SJ; Kim SJ; Kim YK; Park JH; Kweon GR; Kim JM; Lee JU; De Falco V; Jo YS; Shong M
J Clin Endocrinol Metab; 2011 Jan; 96(1):E19-30. PubMed ID: 20926530
[TBL] [Abstract][Full Text] [Related]
11. Iodide- and glucose-handling gene expression regulated by sorafenib or cabozantinib in papillary thyroid cancer.
Ruan M; Liu M; Dong Q; Chen L
J Clin Endocrinol Metab; 2015 May; 100(5):1771-9. PubMed ID: 25768669
[TBL] [Abstract][Full Text] [Related]
12. Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells.
Gu HR; Park SC; Choi SJ; Lee JC; Kim YC; Han CJ; Kim J; Yang KY; Kim YJ; Noh GY; No SH; Jeong JH
Clin Mol Hepatol; 2015 Mar; 21(1):49-59. PubMed ID: 25834802
[TBL] [Abstract][Full Text] [Related]
13. Synergism of ursolic acid derivative US597 with 2-deoxy-D-glucose to preferentially induce tumor cell death by dual-targeting of apoptosis and glycolysis.
Wang J; Jiang Z; Xiang L; Li Y; Ou M; Yang X; Shao J; Lu Y; Lin L; Chen J; Dai Y; Jia L
Sci Rep; 2014 May; 4():5006. PubMed ID: 25833312
[TBL] [Abstract][Full Text] [Related]
14. pAKT Expression and Response to Sorafenib in Differentiated Thyroid Cancer.
Yarchoan M; Ma C; Troxel AB; Stopenski SJ; Tang W; Cohen AB; Pappas-Paxinos M; Johnson BA; Chen EY; Feldman MD; Brose MS
Horm Cancer; 2016 Jun; 7(3):188-95. PubMed ID: 26994002
[TBL] [Abstract][Full Text] [Related]
15. Targeting FLIP and Mcl-1 using a combination of aspirin and sorafenib sensitizes colon cancer cells to TRAIL.
Pennarun B; Kleibeuker JH; Boersma-van Ek W; Kruyt FA; Hollema H; de Vries EG; de Jong S
J Pathol; 2013 Feb; 229(3):410-21. PubMed ID: 23132258
[TBL] [Abstract][Full Text] [Related]
16. Differential glycolytic profile and Warburg effect in papillary thyroid carcinoma cell lines.
Coelho RG; Cazarin JM; Cavalcanti de Albuquerque JP; de Andrade BM; Carvalho DP
Oncol Rep; 2016 Dec; 36(6):3673-3681. PubMed ID: 27748844
[TBL] [Abstract][Full Text] [Related]
17. Validation of VX2 as a Hepatocellular Carcinoma Model: Comparison of the Molecular Reaction of VX2 and HepG2 Tumor Cells to Sorafenib In Vitro.
Nass N; Streit S; Wybranski C; Jürgens J; Brauner J; Schulz N; Powerski M; Ricke J; Kalinski T; Dudeck O; Seidensticker M
Anticancer Res; 2017 Jan; 37(1):87-93. PubMed ID: 28011478
[TBL] [Abstract][Full Text] [Related]
18. Oxidative phosphorylation activation is an important characteristic of DOX resistance in hepatocellular carcinoma cells.
Wu L; Zhao J; Cao K; Liu X; Cai H; Wang J; Li W; Chen Z
Cell Commun Signal; 2018 Feb; 16(1):6. PubMed ID: 29402287
[TBL] [Abstract][Full Text] [Related]
19. Combined inhibition of glycolysis and AMPK induces synergistic breast cancer cell killing.
Wu Y; Sarkissyan M; Mcghee E; Lee S; Vadgama JV
Breast Cancer Res Treat; 2015 Jun; 151(3):529-39. PubMed ID: 25975952
[TBL] [Abstract][Full Text] [Related]
20. 2-Deoxy-d-glucose Promotes Buforin IIb-Induced Cytotoxicity in Prostate Cancer DU145 Cells and Xenograft Tumors.
Wanyan Y; Xu X; Liu K; Zhang H; Zhen J; Zhang R; Wen J; Liu P; Chen Y
Molecules; 2020 Dec; 25(23):. PubMed ID: 33297583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
